HELICOBACTER PYLORI INFECTION

This study is testing a 14-day treatment for Helicobacter pylori, a stomach infection that can cause ulcers and cancer. The treatment uses two drugs, vonoprazan and clarithromycin, and is guided by a stool test to check if the bacteria are resistant to clarithromycin. The goal is…

This study compares two treatments for H. pylori infection, a common stomach bug. One uses a newer drug called tegoprazan, while the other uses a standard proton pump inhibitor. The trial will enroll 400 adults in South Korea, where antibiotic resistance makes treatment difficult…

This study tests whether a newer acid-reducing drug (vonoprazan) works better than a standard one (esomeprazole) for clearing H. pylori, a bacteria that can cause stomach ulcers and indigestion. About 80 adults with H. pylori will take one of the two drug combinations for 14 days…

This study tests whether choosing antibiotics based on lab tests of the bacteria works better than standard antibiotic combinations for people whose H. pylori infection hasn't been cured before. About 450 adults will receive either a tailored or standard regimen for 14 days. The …

This study tests a new way to treat H. pylori, a bacteria that can cause stomach ulcers and cancer. During an endoscopy, doctors fill the stomach with a saltwater solution that is activated by argon plasma to kill the bacteria. The trial will compare two methods of making this so…

This study compares two 14-day antibiotic treatments for Helicobacter pylori infection, a common stomach bug that can cause ulcers. The triple therapy uses bismuth, amoxicillin, and vonoprazan, while the quadruple therapy adds rabeprazole, tetracycline, and metronidazole. Researc…

This study tests three different 14-day treatments for H. pylori, a bacteria that can cause stomach ulcers and cancer. About 390 infected adults will receive either a new triple therapy with bismuth, a dual therapy, or a standard treatment. The goal is to see which works best and…

This study tests different combinations of acid-blocking drugs (P-CABs) with bismuth and antibiotics to treat H. pylori, a stomach infection that can cause ulcers. About 1,730 adults aged 18-70 with confirmed H. pylori will receive one of several treatment regimens. Researchers w…

This study tests a 'screen and treat' approach for H. pylori infection in 14-18 year olds in Chile, where stomach cancer rates are high. Researchers will screen up to 1000 teens and randomly assign 210 persistently infected participants to receive antibiotics or no treatment. The…

This study tests a new two-drug combination (keverprazan and amoxicillin) to treat H. pylori, a stomach infection that can cause ulcers and cancer. About 477 adults will receive different doses and treatment lengths (10 or 14 days) to find the best balance of effectiveness, fewer…

This study tests whether adding a probiotic called Saccharomyces boulardii to a standard antibiotic cocktail helps clear Helicobacter pylori infections that didn't respond to earlier treatments. About 1,248 adults who have failed prior H. pylori therapy will be randomly assigned …

This study tests whether adding bismuth to standard antibiotics works better than antibiotics alone to clear H. pylori infection and heal peptic ulcers in 80 children. Participants take a 14-day treatment, then continue acid-reducing medication for a few more weeks. Researchers w…

This study tests two different 14-day treatments for Helicobacter pylori, a bacteria that can cause stomach ulcers. About 240 adults with confirmed infection will take either tegoprazan or vonoprazan, both combined with amoxicillin. The goal is to see if the newer tegoprazan comb…

This study looks at 2,600 heart attack patients who had a stent placed and also have an H. pylori infection. Half will get a 2-week course of vonoprazan plus amoxicillin to treat the infection, while the other half gets a standard 6-month acid blocker (pantoprazole). The goal is …

This study compares two types of acid-reducing drugs—vonoprazan (a newer drug) and rabeprazole (a standard drug)—when used as part of a 10-day combination therapy for H. pylori infection. About 320 adults with confirmed H. pylori will be randomly assigned to one of the two treatm…

This study tests whether artificial intelligence (AI) can help doctors better detect H. pylori infection and precancerous stomach changes during routine endoscopy. The goal is to see if AI assistance can reduce deaths from stomach cancer. The trial will enroll 6,000 adults aged 2…

This study looks at whether taking common acid-reducing drugs (proton pump inhibitors, or PPIs) affects the accuracy of a stool DNA test for H. pylori, a stomach bacteria. Researchers will test 25 adults who need PPIs, first while on the drug and then after stopping it for 4 week…

This study follows 600 people at higher risk for stomach cancer to track precancerous changes in the stomach lining. Researchers collect tissue, blood, and saliva samples during routine endoscopies. The goal is to understand why some people's stomach changes progress to cancer wh…